Designs and manufactures custom components for medical devices. Produces single-use and single-patient devices for the healthcare industry. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 31% a year over the last 4 years. Every year shown ended in profit.
The gap is $134.2M. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 22% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 31% a year on average.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
On our five-subject report card, UFPT sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: UFPT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.